BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
66.53
+0.10 (0.15%)
At close: Sep 4, 2026, 4:00 PM EDT
67.00
+0.47 (0.71%)
After-hours: Sep 4, 2026, 5:53 PM EDT
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, BioMarin Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $91.42. The average 1-year stock price forecast is 37.41% higher than the current stock price, while the lowest is $60 (-9.82%) and the highest is $124 (+86.38%).
Price Target: $91.42 (+37.41%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 14 | 14 | 13 | 14 |
| Buy | 4 | 5 | 6 | 6 | 6 | 6 |
| Hold | 5 | 5 | 6 | 6 | 6 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 24 | 26 | 26 | 25 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $70 | Hold | Maintains | $70 | +5.22% | Sep 1, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $85 → $86 | Buy | Maintains | $85 → $86 | +29.26% | Sep 1, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $114 | Buy | Maintains | $114 | +71.35% | Sep 1, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $124 | Buy | Reiterates | $124 | +86.38% | Sep 1, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $88 → $90 | Buy | Maintains | $88 → $90 | +35.28% | Sep 1, 2026 |
Financial Forecast
Revenue This Year
3.91B
from 3.22B
Increased by 21.35%
Revenue Next Year
4.47B
from 3.91B
Increased by 14.24%
EPS This Year
5.03
from 3.15
Increased by 59.68%
EPS Next Year
6.54
from 5.03
Increased by 29.99%
EPS and Forward PE are based on non-GAAP adjusted numbers.